Product Images Sunitinib Malate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Sunitinib Malate NDC 63304-094 by Sun Pharmaceutical Industries Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This text presents data on the time of tumor progression in two groups of patients, one treated with a certain therapy ("Suaitiaib") and another group receiving a placebo. The number of patients in each group is mentioned (207 and 105, respectively). The median time of tumor progression for the "Suaitiaib" group was 27.3 weeks, while for the placebo group it was 6.4 weeks. A hazard ratio value of 0.33 is given, along with a 95% confidence interval and a p-value indicating the statistical significance of the difference between the two groups.*
This appears to be a table presenting survival probability data for two different treatments (Sunitinib and IFN-a) consisting of two columns - "Time (weeks)" and "Free Survival Probability (%)" - along with the number of patients at risk, hazard ratio, and confidence interval. However, there seem to be some missing or unreadable characters, making it difficult to provide more detailed information.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.